1. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade follicular non-Hodgkin's lymphoma;Berinstein;Annals of Oncology,1998
2. MIDET + rituximab is an effective regimen for poor prognosis non-Hodgkin's lymphoma patients receiving high dose therapy;Bruno;Blood,2000
3. Stem cell function and engraftment is not affected by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with low grade non-Hodgkin's lymphoma;Buckstein;Seminars in Oncology,1999
4. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: multicenter phase II study;Coiffier;Blood,1998
5. CHOP chemotherapy plus rituximab compared to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL);Coiffier;New England Journal of Medicine,2002